Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading information about the company's clinical trials and safety protocols [1][4][5]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided investors with misleading information regarding the Phase 2 pivotal trial of RP-A501 for Danon disease, while concealing material adverse facts about the safety and clinical trial protocol [4]. - It is alleged that the company failed to disclose serious adverse events, including participant deaths, and made substantive amendments to the trial protocol without informing shareholders [4][5]. - Following the announcement of a clinical hold by the U.S. Food and Drug Administration due to a serious adverse event, the stock price of Rocket Pharmaceuticals reportedly fell [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Rocket Pharmaceuticals securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trial for RP-A501, which resulted in serious adverse events, including patient death [1][4][5]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501 while concealing material adverse facts, including the known risks of serious adverse events [4]. - It is alleged that the company amended the trial protocol to include a new immunomodulatory agent without informing shareholders of this critical update [4]. - Following the announcement of a clinical hold by the FDA due to a serious adverse event resulting in a patient's death, the stock price of Rocket Pharmaceuticals fell significantly [5]. Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7].